Get the Stockscreener App
452.00
0.34%
-1.54
After Hours:
452.00
Alnylam Pharmaceuticals Inc stock is traded at $452.00, with a volume of 751.38K.
It is down -0.34% in the last 24 hours and up +7.90% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$453.54
Open:
$453.45
24h Volume:
751.38K
Relative Volume:
0.73
Market Cap:
$59.25B
Revenue:
$2.46B
Net Income/Loss:
$-319.09M
P/E Ratio:
-183.00
EPS:
-2.47
Net Cash Flow:
$-52.09M
1W Performance:
+1.23%
1M Performance:
+7.90%
6M Performance:
+81.36%
1Y Performance:
+79.74%
1-Day Range:
$444.65
$455.28
1-Week Range:
$441.50
$458.30
52-Week Range:
$205.87
$469.81
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Positive Long-Term HELIOS-B Results for AMVUTTRA - simplywall.st
Is Alnylam Pharmaceuticals Inc. a defensive stockJuly 2025 Momentum & Reliable Breakout Stock Forecasts - خودرو بانک
Is Alnylam Pharmaceuticals Inc. exposed to political riskJuly 2025 Decliners & Community Consensus Trade Signals - خودرو بانک
What are Alnylam Pharmaceuticals Inc.’s earnings expectationsEarnings Beat & Safe Entry Point Alerts - خودرو بانک
Intraday pattern recognizer results for Alnylam Pharmaceuticals Inc.2025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - Newser
Visual analytics tools that track Alnylam Pharmaceuticals Inc. performance2025 Year in Review & Momentum Based Trading Ideas - Newser
Published on: 2025-09-06 00:28:49 - خودرو بانک
Can Alnylam Pharmaceuticals Inc. be the next market leader2025 Investor Takeaways & Reliable Volume Spike Trade Alerts - خودرو بانک
What to expect from Alnylam Pharmaceuticals Inc. in the next 30 days2025 Year in Review & Fast Exit and Entry Strategy Plans - Newser
Published on: 2025-09-05 14:03:59 - Newser
How to use a screener to detect Alnylam Pharmaceuticals Inc. breakoutsPortfolio Performance Summary & Free Fast Gain Swing Trade Alerts - Newser
Using RSI to spot recovery in Alnylam Pharmaceuticals Inc.Rate Cut & Safe Entry Point Identification - Newser
How high can Alnylam Pharmaceuticals Inc. stock goTrend Reversal & Reliable Trade Execution Plans - Newser
Multi asset correlation models including Alnylam Pharmaceuticals Inc.GDP Growth & AI Forecast Swing Trade Picks - Newser
Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock? - Nasdaq
Best data tools to analyze Alnylam Pharmaceuticals Inc. stockWeekly Stock Report & Momentum Based Trading Ideas - Newser
RNA Therapeutics Market Size, Top Share | Industry Report, 2034 - Straits Research
Applying big data sentiment scoring on Alnylam Pharmaceuticals IncMarket Trend Report & High Return Trade Guides - Newser
Gene Therapy Market is expected to reach US$ 35.91 Billion by 2033 - openPR.com
Will Alnylam Pharmaceuticals Inc. outperform small cap indexes2025 Buyback Activity & Real-Time Buy Zone Alerts - خودرو بانک
Key resistance and support levels for Alnylam Pharmaceuticals Inc.2025 AllTime Highs & Weekly Top Gainers Trade List - Newser
Regeneron posts late-stage trial win for myasthenia gravis drug developed with Alnylam - MSN
What does recent volatility data suggest for Alnylam Pharmaceuticals Inc.2025 Trade Ideas & Reliable Intraday Trade Alerts - Newser
Strategies to average down on Alnylam Pharmaceuticals Inc.Market Movers & Safe Entry Point Alerts - Newser
Quantitative breakdown of Alnylam Pharmaceuticals Inc. recent move2025 Technical Overview & Safe Entry Trade Signal Reports - Newser
What moving averages say about Alnylam Pharmaceuticals Inc.2025 Macro Impact & Free Daily Entry Point Trade Alerts - Newser
Using Python tools to backtest Alnylam Pharmaceuticals Inc. strategiesJuly 2025 Summary & Daily Technical Forecast Reports - Newser
Market reaction to Alnylam Pharmaceuticals Inc.’s recent news2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - Newser
Alnylam at Citi’s Biopharma Conference: Launch Success and Future Plans - Investing.com
Sentiment analysis tools applied to Alnylam Pharmaceuticals Inc.July 2025 Opening Moves & Free Weekly Watchlist of Top Performers - Newser
The Strategic Value of Novartis' $5.2 Billion Argo Biopharma Licensing Deal in the RNAi Cardiovascular Therapeutics Space - AInvest
Technical analysis overview for Alnylam Pharmaceuticals Inc. stockJuly 2025 Outlook & Stepwise Trade Signal Implementation - Newser
How institutional ownership impacts Alnylam Pharmaceuticals Inc. stockJuly 2025 Review & Technical Pattern Recognition Alerts - Newser
Technical signs of recovery in Alnylam Pharmaceuticals Inc.July 2025 Volume & Fast Gaining Stock Reports - Newser
Will breakout in Alnylam Pharmaceuticals Inc. lead to full recovery2025 Earnings Surprises & Safe Entry Point Alerts - Newser
What MACD and RSI say about Alnylam Pharmaceuticals Inc.Earnings Summary Report & Weekly High Potential Alerts - Newser
Using fundamentals and technicals on Alnylam Pharmaceuticals Inc.2025 Geopolitical Influence & Weekly Top Performers Watchlists - Newser
Published on: 2025-09-03 01:05:50 - Newser
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives - Seeking Alpha
Alnylam Pharmaceuticals Inc.’s volatility index tracking explained2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
Chart overlay techniques for tracking Alnylam Pharmaceuticals Inc.Forecast Cut & High Accuracy Trade Alerts - Newser
What’s the analyst consensus on Alnylam Pharmaceuticals Inc.Stock Surge & Weekly Return Optimization Plans - خودرو بانک
Alnylam Shares Edge Up 0.11% on $480M Volume (Rank 222nd) as RNAi Pipeline Drives 70%+ Total Return - AInvest
How sentiment analysis helps forecast Alnylam Pharmaceuticals Inc.Quarterly Performance Summary & Weekly Watchlist for Consistent Profits - Newser
Is Alnylam Pharmaceuticals Inc. forming a breakout pattern2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - خودرو بانک
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):